Consistently, the same variant demonstrated a nominal association with reduced likelihood of achieving ≥75% improvement (<i>p</i> = 0.065).<h4>Conclusions</h4>Although limited by sample size, these findings suggest potential treatment-specific pharmacogenetic effects within the IL6 pathway, supporting further investigation in larger cohorts to inform personalized therapeutic strategies in eczema. This evidence concerns the gene IL6 and Eczematoid dermatitis.